On January 30, the first meeting of the Coordination Board, a COMECT (Coordination Mechanism for Cohorts and Trials) activity, was held, gathering together the Cohort Coordination Board (CCB) and the Trial Coordination Board (TCB).
Representatives of the existing network and infrastructure were present, including the TCB Tx Pillar and the Vaccine Pillar. Among the discussion points, the presentation of results from the adoption of data standards survey.
The “Cohort Coordination Board” (CCB) groups the existing COVID-19 cohort projects. The purpose is to establish a structured collaboration among cohort-based research projects and other relevant initiatives. The CCB includes, other than European Commission representatives, all the EU-funded projects conducting COVID-19 cohort-based research and other relevant initiatives such as the European COVID-19 Data Platform, partners from industry and other stakeholders (e.g. EMA and ECDC).
The Trial Coordination Board (TCB) aims to establish collaboration and cooperation between the European COVID-19 adaptative platform trials (APT) and create and maintain the bridge with regulatory bodies, policy makers and global COVID-19 trials. This Coordination board is composed by some of the main people that are able to implement and develop this European COVID-19 APTs with success. It is divided in two pillars: the therapeutic pillar and the vaccine pillar.